Global expansion BioReliance and MilliporeSigma are expanding facilities and biosafety testing capabilities internationally, including recent openings in Singapore and Germany, signaling opportunities for multinational CROs, clinical trial support, and regulatory testing partnerships.

Regulatory testing demand With a focus on GMP and GLP testing services and over 1,000 tests for biologics safety and product characterization, there is strong potential to upsell advanced regulatory compliance testing, method development, and batch release support to biotech and pharma clients navigating FDA and MHRA requirements.

Sustainability leadership Award recognition for corporate social responsibility and sustainability suggests opportunities to align with customers’ ESG goals, offering sustainable testing workflows, green chemistry options, and transparent reporting to attract bioscience partners prioritizing responsible innovation.

Funding and scale Mid-market revenue range and ongoing facility investments indicate capacity for larger, multi-site testing programs, pilot studies, and long-term contracts with pharma/biotech companies seeking scalable supply chains and global lab access.

Technology integration Adoption of a broad tech stack including Salesforce, WordPress, Qualtrics, and analytics platforms points to opportunities for selling integrated CRM-driven account management, customer experience improvements, and streamlined data capture for long-term client success programs.